Project Grant R41HL167504
Award Date
8/15/23
Completion Date
7/31/24
Dollars Obligated
$299K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
South Carolina, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded Novomedix LLC a $306,872 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to develop novel oral small molecule therapeutics for the treatment of progressive pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF). The goal is to create a safer and more effective therapy compared to the currently approved drugs, which only slow disease progression and have significant side effects. Novomedix will...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $695,403 project grant under the Cardiovascular Diseases Research (CFDA 93.837) program to the University of Arizona to conduct research aimed at developing new therapeutic approaches to inhibit the progression of pulmonary fibrosis. The key objectives of the 4-year project are to: Determine whether restoring microvascular integrity through nanoparticle gene therapy can inhibit lung fibrogenesis. Define whether transplantation of...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a 4-year, $2,323,927 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Regents of the University of California, San Francisco (UCSF). The grant will fund research to investigate the emergence, fate, and functional role of inflammatory fibroblasts in the development of pulmonary fibrosis. Key objectives include: Comparing the timing, persistence, and fate of inflammatory fibroblasts in mouse models...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $464,121 to The Medical University of South Carolina to develop peptides derived from collagen XVIII for the treatment of pulmonary fibrosis. The project aims to simultaneously test the identified peptides in preclinical models of fibrosis, identify a lead candidate, characterize its efficacy, conduct dose escalation...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is funding the development of a novel drug candidate to treat idiopathic pulmonary fibrosis (IPF). The award of $356,250 will support a two-phase project by Vasarya Therapeutics, Inc. to perform affinity maturation and liability assessment on a tool compound called VSR-H5, which has demonstrated the ability to selectively target and inhibit...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will provide $542,402 in funding to support research conducted by the collaborative partnership between Henry Ford Health and Michigan State University Health Sciences. The goal of the project is to identify small molecules that can reverse profibrotic gene signatures in idiopathic pulmonary fibrosis (IPF), a devastating lung disease...
This federal Project Grant award for $595,286.00, provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to investigate a previously unappreciated mechanism of regulating collagen clearance in the lungs. The research seeks to delineate the pathways and upstream/downstream mechanisms governing a cellular homeostatic feedback loop that senses collagen synthesis and regulates its clearance. This work will use mouse...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $1,546,880.00 to the University of Pittsburgh to conduct research on the regulation of myofibroblasts in idiopathic pulmonary fibrosis (IPF). The research aims to determine the "regulatory architecture" of open chromatin in myofibroblasts, evaluate how expression of E-box transcription factors regulates myofibroblast...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop an adeno-associated virus (AAV)-mediated gene therapy as a treatment for idiopathic pulmonary fibrosis (IPF). The $1,193,262 grant, awarded on September 6, 2024, will fund research to validate the efficacy of the AAV-SPL therapy in preclinical IPF models and optimize its pharmacological characteristics. The University of...
This Project Grant award of $389,754 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to assess the therapeutic potential of a peptide derived from collagen XVIII for treating lung fibrosis associated with systemic sclerosis (scleroderma). The project aims to evaluate the anti-fibrotic effects of this peptide in a murine model of lung fibrosis, as well as identify the minimal effective dose, optimal...